Atezolizumab plus pirfenidone for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 1/2 trial tests whether combining atezolizumab and pirfenidone can help people with non-small cell lung cancer (NSCLC) after prior treatment. It is aimed at patients whose cancer has certain genetic markers ruled out and who can safely take study medicines and follow frequent visits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can sign consent (or your legal representative can).
- You have confirmed non-small cell lung cancer that is advanced (stage IV) or coming back, or unresectable stage III that can’t be removed by surgery.
- Your cancer tests show no “actionable” gene changes (like EGFR, ALK, or ROS-1).
- You have at least one measurable tumor spot that doctors can track on scans.
- You must be able to take pills by mouth, attend scheduled visits, and complete required blood/organ tests.
- Your lung/heart health must be safe for this study (including good enough organ function and heart tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of two drugs, cabozantinib and atezolizumab, for people with advanced lung cancer that has low PD-L1 levels. The goal is to see if this combination can shrink tumors and help control the cancer.
This trial tests a drug called atezolizumab, which helps the immune system fight cancer, for people with advanced lung cancer (non-small cell lung cancer) that has not been treated yet. It is for tumors with high levels of PD-L1, a protein that can help cancer hide from the immune system.
This trial looks at adding atezolizumab to chemotherapy before surgery for resectable, non-squamous non-small cell lung cancer. It also tries to predict which patients will respond best using your tumor tissue.
This trial studies whether combining tocilizumab with atezolizumab can help people with advanced lung cancer that has already stopped responding to an immune checkpoint medicine. It may help when standard immune therapy (and other treatments) aren’t working anymore.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a new drug called BL-M14D1 combined with atezolizumab (an immunotherapy) against standard chemotherapy for extensive-stage small cell lung cancer, a serious type of lung cancer that has spread. The goal is to see if this combination helps patients live longer and control their cancer better.
Hear when a new NSCLC Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.